Amicus Therapeutics

FOLD Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$14.44

+0% today

52W: $5.51 – $14.46

52W Low: $5.51 Position: 99.8% 52W High: $14.46

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

17.63x

Forward Price/Earnings

P/S Ratio

7.15x

Price-to-Sales

EV/EBITDA

111.63x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$4.5B

Market Capitalization

Revenue Growth

23.7%

YoY Revenue Growth

Profit Margin

-4.28%

Net profit margin

ROE

-11.58%

Return on Equity

Beta

0.48

Market sensitivity

Short Interest

6.47%

% of float sold short

Avg. Volume

5,743,867

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Hold

5 analysts

Avg. Price Target

$14.50

+0.42% upside

Target Range

$14.50 – $14.50

About the Company

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Ga

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 511 Exchange: NGM